{
    "medicine_id": "f78dd715261fbe759ed24aeb742ade865a765bf5",
    "platform_id": "DB05471",
    "metadata": {
        "name": "Adult Formula 50 60 61 v v Solution",
        "composition": "60 61 v v SGN 30",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in autoimmune diseases cancer tumors unspecified lymphoma non hodgkin s and lymphoma unspecified",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "SGN 30 a monoclonal antibody with activity against CD30 malignancies Through investigation of the mechanisms underlying SGN 30 s antitumor activity SGN 30 treatment was found to activate NF kappaB and modulation of several messages including the growth regulator p21WAF1 CIP1 p21 and cellular adhesion marker ICAM 1 p21 protein level changes are believed to be associated with arresting cell growth In addition to directly killing cancerous cells SGN 30 affects growth arrest and drug sensitization through growth regulating and proapoptotic machinery SGN 30 could therefore be used to increase the efficacy of standard chemotherapies used to treat patients with CD30 malignancies",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}